Surfin Meta Digital Technology Pte Ltd (“Surfin”) Welcomes John Quelch and John Fennell to its Board of Directors
14.4.2023 05:00:00 EEST | Business Wire | Press release
Surfin group of companies (“Surfin Group”), headquartered in Singapore, a leading provider of digital financial solutions for under-serviced clients in emerging markets, is pleased to announce the appointments of John Quelch and John Fennell to its Board of Directors. These two highly experienced professionals bring an extensive wealth of expertise in marketing, global business strategy, risk management, and leadership to the Surfin Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005053/en/
Dr. Quelch is a highly respected expert in international strategy, global marketing, and ESG with more than five decades of experience serving as a non-executive director of public companies in the USA and UK. As a member of Surfin’s board of directors, Quelch brings a wealth of experience in corporate governance, strategic planning, and ESG initiatives. He has served on the boards of several important public companies, including Alere, Aramark, Gentiva Health Services, Pepsi Bottling Group, and WPP. He has also served as Dean of both the China Europe International Business School and London Business School. "I am excited to join Surfin Group's board of directors and to work with the company's talented leadership team," said Quelch. "Surfin Group is at the forefront of providing inclusive finance through its innovative digital solutions to emerging markets, and I look forward to contributing my expertise to support the company's growth and success." Quelch was awarded the CBE (Commander of the Order of the British Empire).
John Fennell, a seasoned risk management professional, will bolster Surfin Group's efforts to optimize its risk and control environment as the company looks to expand its digital financial technology offerings, including robo-advisor wealth management and digital security trading for Millennials and Gen Z in developing countries. Mr. Fennell has previously served as Chief Risk Officer of the Options Clearing Corporation, overseeing risk at multiple organizations responsible for systemic resilience of financial markets. His participation in serving on the committees of World Federation of Exchanges and CCP12 will prove invaluable as the company seeks to develop cross-border trading products and engage with local exchanges. Fennell shared his thoughts on the appointment, saying, "I'm thrilled to be part of Surfin Group's mission to promote financial inclusion and innovation in developing countries. I look forward to applying my risk management expertise to ensure the company's continued success and growth."
Yanan Wu, CFA, Ph.D, Chairman of Surfin Group, expressed the company's enthusiasm about the appointments of Dr. Quelch and Mr. Fennell: "We are thrilled to welcome both John Quelch and John Fennell to our Board of Directors. We are confident that their combined expertise and experience will significantly contribute to our growth and help us achieve our ambitions of becoming a forefront leader in digital financial technologies, promoting transparency, innovation, and financial inclusion in developing countries."
About Surfin Group
Surfin Group, headquartered in Singapore, is a leading provider of digital financial solutions for under-serviced clients in emerging markets. The group is committed to providing innovative digital solutions to its clients, with a focus on transparency, inclusion, innovation, and compassion. For more information, please visit www.surfin.sg.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005053/en/
Contact information
Media:
Daju Gu, Board Secretary
Email: daju.gu@surfin.sg
Phone: +1 416 414 3426
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
